The use of nonsteroidal anti-inflammatory drugs by COVID-19 patients – in a nutshell

Show simple item record

dc.contributor.author Flepisi, Brian Thabile
dc.contributor.author Schellack, Natalie
dc.date.accessioned 2022-07-29T07:05:46Z
dc.date.available 2022-07-29T07:05:46Z
dc.date.issued 2021-06
dc.description.abstract Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a large scale of morbidities and mortalities worldwide, posing a significant threat to global health. COVID-19 has been challenging due to a lack of established treatment guidelines. Nonsteroidal anti-inflammatory drugs (NSAIDs) comprise of a heterogeneous group of compounds used for the symptomatic relief of fever, pain and inflammation. NSAIDs exert their effects by inhibiting prostaglandins' biosynthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects. They may be beneficial in reducing inflammation and prevent fatal cytokine storms in COVID-19. However, the use of NSAIDs by COVID-19 patients has been controversial, with some reports recommending their use, while others contraindicated them. This may be due to the heterogeneous nature of COVID-19 including different strains or cases. There seem to be COVID-19 cases where NSAIDs should not be used; however, there is no evidence that NSAIDs should be avoided in all COVID-19 patients. en_US
dc.description.department Pharmacology en_US
dc.description.uri http://www.sapj.co.za en_US
dc.identifier.citation Flepisi, B.T. & Schellack, N. 2021, 'The use of nonsteroidal anti-inflammatory drugs by COVID-19 patients–in a nutshell', SA Pharmaceutical Journal, vol. 88, no. 3, pp. 35-38, doi : 10.520/ejc-mp_sapj_v88_n3_a8. en_US
dc.identifier.isbn 10.520/ejc-mp_sapj_v88_n3_a8
dc.identifier.issn 2221-5875 (print)
dc.identifier.issn 2220-1017 (online)
dc.identifier.uri https://repository.up.ac.za/handle/2263/86585
dc.language.iso en en_US
dc.publisher Medpharm Publications en_US
dc.rights © Medpharm. This article is licensed under a This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.5 South Africa License. en_US
dc.subject Inflammation en_US
dc.subject Pain en_US
dc.subject Ibuprofen en_US
dc.subject Diclofenac en_US
dc.subject Aspirin en_US
dc.subject Naproxen en_US
dc.subject Indomethacin en_US
dc.subject Paracetamol en_US
dc.subject Non-steroidal anti-inflammatory drug (NSAID) en_US
dc.subject COVID-19 pandemic en_US
dc.subject Coronavirus disease 2019 (COVID-19) en_US
dc.subject Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) en_US
dc.title The use of nonsteroidal anti-inflammatory drugs by COVID-19 patients – in a nutshell en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record